Two Sigma Investments’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14M | Buy |
271,228
+150,562
| +125% | +$7.67M | 0.01% | 1186 |
|
|
2025
Q4 | $6M | Sell |
120,666
-137,310
| -53% | -$6.68M | 0.01% | 1554 |
|
|
2025
Q3 | $12.3M | Buy |
257,976
+200,671
| +350% | +$8.08M | 0.02% | 846 |
|
|
2025
Q2 | $1.81M | Sell |
57,305
-39,919
| -41% | -$1.28M | ﹤0.01% | 1912 |
|
|
2025
Q1 | $3.18M | Buy |
97,224
+72,237
| +289% | +$2.56M | 0.01% | 1407 |
|
|
2024
Q4 | $904K | Sell |
24,987
-59,580
| -70% | -$2.1M | ﹤0.01% | 2241 |
|
|
2024
Q3 | $2.64M | Buy |
84,567
+36,006
| +74% | +$1.12M | 0.01% | 1501 |
|
|
2024
Q2 | $1.3M | Buy |
48,561
+25,109
| +107% | +$728K | ﹤0.01% | 1842 |
|
|
2024
Q1 | $800K | Sell |
23,452
-171,330
| -88% | -$5.1M | ﹤0.01% | 2091 |
|
|
2023
Q4 | $5.64M | Buy |
194,782
+127,751
| +191% | +$3.39M | 0.01% | 928 |
|
|
2023
Q3 | $1.85M | Sell |
67,031
-190,195
| -74% | -$5.79M | 0.01% | 1454 |
|
|
2023
Q2 | $7.73M | Buy |
257,226
+48,422
| +23% | +$1.69M | 0.02% | 751 |
|
|
2023
Q1 | $7.56M | Buy |
208,804
+70,187
| +51% | +$2.7M | 0.02% | 710 |
|
|
2022
Q4 | $4.94M | Buy |
138,617
+35,569
| +35% | +$1.24M | 0.02% | 868 |
|
|
2022
Q3 | $3.49M | Buy |
+103,048
| New | +$3.35M | 0.01% | 898 |
|
|
2022
Q2 | – | Sell |
-18,389
| Closed | -$594K | – | 2916 |
|
|
2022
Q1 | $594K | Buy |
+18,389
| New | +$564K | ﹤0.01% | 1938 |
|
|
2021
Q3 | – | Sell |
-38,592
| Closed | -$1.19M | – | 4682 |
|
|
2021
Q2 | $1.19M | Sell |
38,592
-211,775
| -85% | -$6.49M | ﹤0.01% | 2327 |
|
|
2021
Q1 | $6.55M | Buy |
250,367
+192,120
| +330% | +$5.37M | 0.02% | 909 |
|
|
2020
Q4 | $1.47M | Buy |
+58,247
| New | +$1.25M | ﹤0.01% | 1716 |
|
|
2020
Q3 | – | Sell |
-294,948
| Closed | -$7M | – | 3537 |
|
|
2020
Q2 | $7M | Buy |
294,948
+87,986
| +43% | +$1.94M | 0.03% | 510 |
|
|
2020
Q1 | $3.72M | Buy |
206,962
+123,876
| +149% | +$2.6M | 0.03% | 640 |
|
|
2019
Q4 | $1.97M | Buy |
+83,086
| New | +$2.02M | 0.01% | 1603 |
|
|
2019
Q3 | – | Sell |
-154,739
| Closed | -$5.12M | – | 3773 |
|
|
2019
Q2 | $5.12M | Sell |
154,739
-193,884
| -56% | -$6.64M | 0.02% | 884 |
|
|
2019
Q1 | $12.2M | Buy |
+348,623
| New | +$13M | 0.04% | 581 |
|
|
2018
Q2 | – | Sell |
-86,249
| Closed | -$3.95M | – | 3634 |
|
|
2018
Q1 | $3.95M | Buy |
86,249
+19,489
| +29% | +$813K | 0.01% | 1089 |
|
|
2017
Q4 | $2.66M | Buy |
+66,760
| New | +$2.64M | 0.01% | 1279 |
|
|
2017
Q3 | – | Sell |
-5,403
| Closed | -$233K | – | 3168 |
|
|
2017
Q2 | $233K | Buy |
+5,403
| New | +$192K | ﹤0.01% | 2742 |
|
|
2016
Q1 | – | Sell |
-27,234
| Closed | -$366K | – | 3110 |
|
|
2015
Q4 | $366K | Buy |
+27,234
| New | +$421K | ﹤0.01% | 2145 |
|
|
2015
Q2 | – | Sell |
-216,110
| Closed | -$2.61M | – | 3075 |
|
|
2015
Q1 | $2.61M | Buy |
216,110
+137,033
| +173% | +$1.29M | 0.01% | 1029 |
|
|
2014
Q4 | $656K | Buy |
+79,077
| New | +$664K | ﹤0.01% | 1585 |
|
|
2014
Q1 | – | Sell |
-119,926
| Closed | -$904K | – | 2245 |
|
|
2013
Q4 | $904K | Buy |
+119,926
| New | +$838K | 0.01% | 1378 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Two Sigma Investments's SUPN Position: Q1 2026 in Review
Two Sigma Investments increased its Supernus Pharmaceuticals (SUPN) stake by 125% in Q1 2026, buying an estimated $7.67M and bringing the position to 271,228 shares worth $14M. The position accounts for 0.01% of the portfolio, ranked #1186.
Two Sigma Investments first reported a position in SUPN in Q4 2013 and has held it in 31 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Two Sigma Investments held 271,228 shares of Supernus Pharmaceuticals worth $14M as of Q1 2026.
- Two Sigma Investments bought 150,562 Supernus Pharmaceuticals shares in Q1 2026, an estimated $7.67M.
- Supernus Pharmaceuticals made up 0.01% of Two Sigma Investments's portfolio in Q1 2026, its #1186 holding.
- Two Sigma Investments first reported a position in Supernus Pharmaceuticals in Q4 2013 and has held it in 31 quarters since.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.